开发一种带有硫代硫酸盐配体的亚硝基铁复合物口服剂型，这是一种外源性一氧化氮（NO）供体

IF 0.8 4区医学 Q4 CHEMISTRY, MEDICINAL Pharmaceutical Chemistry Journal Pub Date : 2024-07-13 DOI:10.1007/s11094-024-03170-6

V. O. Novikova, O. V. Pokidova, N. A. Sanina

{"title":"开发一种带有硫代硫酸盐配体的亚硝基铁复合物口服剂型，这是一种外源性一氧化氮（NO）供体","authors":"V. O. Novikova, O. V. Pokidova, N. A. Sanina","doi":"10.1007/s11094-024-03170-6","DOIUrl":null,"url":null,"abstract":"The composition and technology for obtaining a solid dosed stable dosage form of a promising representative of the class of nitrogen monoxide (NO) donors, an anionic tetranitrosyl iron complex with thiosulfate ligands Na2[Fe2(S2O3)2(NO)4]·4H2O, were developed. The rate of NO generation by the complex could be modulated by using different types of excipients or by varying their concentrations. Albumin was found to be the optimal prolonging agent in the manufacture of this dosage form. The developed dosage form expanded the arsenal of long-acting NO-donor medicines used to treat socially significant diseases.","PeriodicalId":19990,"journal":{"name":"Pharmaceutical Chemistry Journal","volume":"14 1","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of a Peroral Dosage Form of a Nitrosyl Iron Complex with Thiosulfate Ligands, an Exogenous Nitric Oxide (NO) Donor\",\"authors\":\"V. O. Novikova, O. V. Pokidova, N. A. Sanina\",\"doi\":\"10.1007/s11094-024-03170-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The composition and technology for obtaining a solid dosed stable dosage form of a promising representative of the class of nitrogen monoxide (NO) donors, an anionic tetranitrosyl iron complex with thiosulfate ligands Na2[Fe2(S2O3)2(NO)4]·4H2O, were developed. The rate of NO generation by the complex could be modulated by using different types of excipients or by varying their concentrations. Albumin was found to be the optimal prolonging agent in the manufacture of this dosage form. The developed dosage form expanded the arsenal of long-acting NO-donor medicines used to treat socially significant diseases.\",\"PeriodicalId\":19990,\"journal\":{\"name\":\"Pharmaceutical Chemistry Journal\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-07-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Chemistry Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11094-024-03170-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Chemistry Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11094-024-03170-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

本研究开发了一氧化氮（NO）供体类中一种很有前途的代表--具有硫代硫酸盐配体的阴离子四亚硝基铁络合物 Na2[Fe2(S2O3)2(NO)4]-4H2O 的组成和技术，以获得剂量稳定的固体剂型。通过使用不同类型的辅料或改变辅料的浓度，可以调节络合物生成 NO 的速率。研究发现，白蛋白是制造这种剂型的最佳延长剂。所开发的剂型扩大了用于治疗重大社会疾病的长效 NO 供体药物库。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Development of a Peroral Dosage Form of a Nitrosyl Iron Complex with Thiosulfate Ligands, an Exogenous Nitric Oxide (NO) Donor

The composition and technology for obtaining a solid dosed stable dosage form of a promising representative of the class of nitrogen monoxide (NO) donors, an anionic tetranitrosyl iron complex with thiosulfate ligands Na₂[Fe₂(S₂O₃)₂(NO)₄]·4H₂O, were developed. The rate of NO generation by the complex could be modulated by using different types of excipients or by varying their concentrations. Albumin was found to be the optimal prolonging agent in the manufacture of this dosage form. The developed dosage form expanded the arsenal of long-acting NO-donor medicines used to treat socially significant diseases.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmaceutical Chemistry Journal CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

1.30

自引率

22.20%

发文量

226

审稿时长

3-8 weeks

期刊介绍： Pharmaceutical Chemistry Journal is a monthly publication devoted to scientific and technical research on the creation of new drugs and the improvement of manufacturing technology of drugs and intermediates. International contributors cover the entire spectrum of new drug research, including: methods of synthesis; results of pharmacological, toxicological, and biochemical studies; investigation of structure - activity relationships in prediction of new compounds; methods and technical facilities used; and problems associated with the development of ecologically safe and economically feasible methods of industrial production. In addition, analytical reviews of the international literature in the field provide coverage of the most recent developments around the world. Pharmaceutical Chemistry Journal is a translation of the Russian journal Khimiko-Farmatsevticheskii Zhurnal. The Russian Volume Year is published in English from April. All articles are peer-reviewed.